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Objectives
To identify and implement strategies that help meet
safety monitoring requirements in the context of an
observational study for artemether-lumefantrine (AL)
administered as first-line treatment for uncomplicated
malaria in rural Tanzania.
Methods
Pharmacovigilance procedures were developed through
collaboration between the investigating bodies (Ifakara
Health Institute and Swiss Tropical and Public Health
Institute), the relevant regulatory authority (Tanzania
Food and Drugs Authority) and the manufacturer of AL
(Novartis Pharma AG). Training and refresher sessions
on the pharmacovigilance system were provided for
healthcare workers from local health facilities and field
recorders of the Ifakara Health Demographic Surveil-
lance System (IHDSS). Three distinct channels for iden-
tification of adverse events (AEs) and serious adverse
events (SAEs) were identified and implemented.
Results
Training was provided for 40 healthcare providers (with
refresher training 18 months later) and for six field
recorders. During the period 1
st September 2007 to 31
st
March 2010, 57 AEs were reported (including 43 under
AL, four under sulphadoxine-pyrimethamine, one under
metakelfin, two after antibiotics). The remaining seven
were due to anti-pyretic or anti-parasite medications.
Twenty patients experienced SAEs; in 16 cases, a rela-
tion to AL was suspected. Six of the 20 cases were
reported within 24 hours of occurrence. In all cases
reported after AL, 5 cases (vomiting), 16 cases (itching
and/or rash) and others were difficult breathing, convul-
sion and headache (10 cases). The four AEs that
occurred after SP were mild erythematic skin lesions
that did not progress to Stevens-Johnson syndrome.
The AEs seen following treatment with penicillin and
amoxicillin were both rashes.
Discussion
Safety monitoring and reporting is possible even in
settings with weak health infrastructure. Reporting can
be enhanced by regular and appropriate training of
healthcare providers. SMS text alerts provide a practical
solution to communication challenges.
Conclusion
Experience gained in this setting could help to improve
spontaneous reporting of AEs and SAEs to health
authorities or marketing authorization holders.
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